Work

Efficacy of second-line therapies for SMARCA4-mutated NSCLC based on a nationwide comprehensive genomic profiling database

Year: 2026
Type: article
Abstract: Clinical data on existing therapies for SMARCA4 -mutated tumors are scarce, hindering the development of new agents targeting these mutations. Querying the Japanese C-CAT database, we analyzed non-small cell lung cancer (NSCLC) patients with oncogenic SMARCA4 mutations receiving docetaxel (DTX) alone or DTX plus ramucirumab (RAM) as second-line therapy following chemoimmunotherapy. The primary endpoint was the objective response rate (ORR). Among the 96,973 patients registered in C-CAT, 324 with oncogenic SMARCA4 -mutated NSCLC were identified. After first-line chemoimmunotherapy, 13 of these 324 patients received DTX alone and 52 received DTX+RAM. The ORR was 23.1% for DTX alone and 21.2% for DTX+RAM. Median time to next treatment was 4.0 months for DTX alone and 4.9 months for DTX+RAM. These findings clarify second-line DTX and DTX+RAM efficacy, establishing a benchmark for evaluating future therapies. Additionally, STK11 and KEAP1 co-mutations were characterized but showed no association with survival or second-line treatment outcomes.
Source: iScience
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,240
OpenAlex ID: W7125934979
FWCI:
Cites: 23
Cited by:
Related to: 10